UBIO - ProShares UltraPro Nasdaq Biotechnology

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
30.05
+1.86 (+6.60%)
As of 3:31PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close28.19
Open28.73
Bid30.07 x 700
Ask30.14 x 300
Day's Range28.50 - 30.38
52 Week Range24.43 - 46.35
Volume73,123
Avg. Volume102,266
Net Assets35M
NAV31.82
PE Ratio (TTM)N/A
Yield0.00%
YTD Return-5.38%
Beta (3y)0.00
Expense Ratio (net)0.95%
Inception Date2015-06-22
Trade prices are not sourced from all markets
  • ETF Trends7 months ago

    Biotech, Pharma ETFs Leave Pricing Drama Behind

    Biotechnology and pharmaceutical ETFs have rallied in recent weeks as drug pricing concerns wane and investors look to the opportunity of this market segment. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) ...

  • ETF Trends8 months ago

    Biotech ETF Investing is Hot, Can Get Hotter

    Up more than 42% year-to-date, the SPDR S&P Biotech ETF (NYSEArca: XBI ) , one of the largest biotechnology ETFs, is one of this year's best-performing non-leveraged ETFs. That does not mean XBI's run ...

  • ETF Trends8 months ago

    Biotech ETFs Remain Bell of the Ball

    The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB) , the largest biotechnology exchange traded fund by assets, and its equal-weight rival, the SPDR S&P Biotech ETF (NYSEArca: XBI) have been soaring in ...

  • ETF Trends8 months ago

    Biotech ETF Investing is Starting to Look Good – Here’s Why

    The SPDR S&P Biotech ETF (NYSEArca: XBI) , one of the largest biotechnology exchange traded funds, is getting in on the sector's resurgence. XBI, an equal-weight fund, is up about 7% over the past week, ...

  • ETF Trends8 months ago

    September Could be Kind to Biotechnology ETFs

    The iShares Nasdaq Biotechnology ETF (NASDAQGM:  IBB ) , the largest biotechnology exchange traded fund by assets, is up nearly 18% and the behemoth biotech fund could add to those gains in September. ...

  • Market Realist9 months ago

    Biogen’s Interferons Witnessed Steady Growth in 2Q17

    In 2Q17, Biogen’s (BIIB) net revenue from the sale of interferons amounted to ~$691 million, a 5% fall year-over-year (or YoY) and a ~7% rise quarter-over-quarter.

  • Too Late To Catch Biotech Rally As Trump Fears Subside?
    Investor's Business Daily10 months ago

    Too Late To Catch Biotech Rally As Trump Fears Subside?

    With names like AbbVie and Celgene on a tear the past week, many biotech sector ETFs hit 52-week or longer highs.